Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Proof-of-Concept Study Evaluating Safety, Tolerability, and Preliminary Efficacy of EOM613 in COVID-19 Infected Patients With Severe Symptoms

NCT05212532 is registered in ClinicalTrials.gov with EOM Pharmaceuticals as lead sponsor.

NCT NCT05212532
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05212532 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Proof-of-Concept Study Evaluating Safety, Tolerability, and Preliminary Efficacy of EOM613 in COVID-19 Infected Patients With Severe Symptoms
Lead sponsor
EOM Pharmaceuticals
Phase
Phase 1
Overall status
Unknown status
Start date
August 9, 2021
Completion date
March 30, 2022
Enrollment
40 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19 acute respiratory distress syndrome, covid-19 pneumonia, covid-19 respiratory infection